Nimbus Therapeutics Obtains $43,000,000 Series B Funding

  • Feed Type
  • Date
  • Company Name
    Nimbus Therapeutics
  • Mailing Address
    25 First Street Cambridge, MA 02141 USA
  • Company Description
    Nimbus Therapeutics is a biotechnology company that is pioneering a new computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinical development. We are designing highly selective and potent medicines to disrupt known drivers of serious diseases, including metabolic disease, cancer and immune-inflammatory disorders.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series B
  • Proceeds Purposes
    Nimbus plans to use the funds from the Series B round to advance its lead program, an Acetyl CoA Carboxylase (ACC) inhibitor, into clinical development, representing the first allosteric and liver-targeted inhibitor intended for the treatment of Non-alcoholic Steatohepatitis, or NASH, an increasingly common liver disease which is estimated to affect 16 million Americans. Nimbus plans to report Phase 1 data from this program later this year. Additionally, the company will continue to advance its preclinical programs of novel small molecules including those for IRAK4, Tyk2, KRas and other medically-important targets.
  • M&A Terms
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor

Trending on Xconomy